A Phase II Proof of Principle Study of the Activity of Pembrolizumab (MK-3475) in Combination With SBRT in Primary Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer (mRCC) Patients
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Renal cancer
- Focus Proof of concept; Therapeutic Use
- 29 Dec 2016 Status changed from not yet recruiting to recruiting.
- 21 Nov 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2017.
- 13 Nov 2015 New trial record